The IMPROVE trial, a phase II study investigating intermittent versus continuous panitumumab plus FOLFIRI in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC), has provided key insights into optimizing first-line treatment strategies.
Professor Alberto Sobrero played a crucial role in this study, contributing to the provision of study materials, data collection, and data interpretation. His expertise was instrumental in shaping the study’s methodology and ensuring the robustness of the analysis. By evaluating the feasibility of an intermittent treatment strategy, the study demonstrated that intermittent therapy maintains comparable survival outcomes while reducing skin-related toxicity.
With a 12-month progression-free survival on treatment (PFSot) rate of 58.5% in the intermittent arm versus 45.7% in the continuous arm, these findings suggest that intermittent therapy may help delay resistance evolution and improve patient compliance. If validated in the IMPROVE-2 phase III trial, this approach could provide a more tolerable and effective treatment option for patients with unresectable mCRC.
Professor Sobrero’s extensive experience in colorectal cancer research continues to drive meaningful advancements in precision oncology and clinical practice.
